ExelixisvsMerck & Company

EXEL and MRK stock compared: price, dividend, valuation and results, from SEC filings.

EXEL

Exelixis, Inc.

$68.29

Value $16.7B

-0.31%
EXEL's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Exelixis (EXEL) has a market value of $16.7B and Merck & Company (MRK) $341B. Over the last year, with dividends, EXEL moved +61.0% and MRK +52.7%. The P/E is 18.8 for EXEL and 138.9 for MRK. Dividend yield: EXEL none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    EXEL$16.7B

    MRK$341B

    MRK is 20 times EXEL

  • Revenue, 12 months

    EXEL$2.5B

    MRK$67.4B

    MRK is 27 times EXEL

  • Net income, 12 months

    EXEL$885M

    MRK$2.5B

    MRK is 2.8 times EXEL

  • Operating margin

    EXEL40.2%

    MRK–

  • ROIC

    EXEL39.9%

    MRK3.9%

    36.0 points apart

  • P/E

    EXEL18.8

    MRK138.9

    MRK is 7.4 times EXEL

  • Dividend yield

    EXEL0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    EXEL+281.9%

    MRK+94.3%

    187.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

EXEL+281.9%

MRK+94.3%

10020030040020222023202420252026
Returns by period
PeriodEXELWith dividendsMRKWith dividends
1 year since November 17, 2025+61.0%Price +61.0%+52.7%Price +48.4%
3 years since November 17, 2023+223.2%+47.8% a yearPrice +223.2%+48.4%+14.1% a yearPrice +35.4%
5 years since November 17, 2021+281.9%+30.7% a yearPrice +281.9%+94.3%+14.2% a yearPrice +66.8%
10 years since November 18, 2016+302.7%+14.9% a yearPrice +302.7%+216.6%+12.2% a yearPrice +133.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

EXELExelixisMRKMerck & Company

Valuation

EXELMRK
Valuation
Price$68.29$137.78
Market value$16.7B$341B
Enterprise value (EV)$15.8B$385B
P/E18.8138.9
P/E, 5-year median25.414.8
P/B9.17.6
EV/EBIT15.780.8
Free cash flow yield7.0%4.3%

Results and growth

EXELMRK
Results and growth
Revenue, 12 months$2.5B$67.4B
Net income, 12 months$885M$2.5B
Free cash flow, 12 months$1.2B$14.7B
Earnings per share, 12 months$3.34$0.98
Revenue growth, year on year7.0%1.3%
Revenue growth a year, past+18.6%over 5 years+9.4%over 5 years
EPS growth a year, past+51.3%over 5 years+21.2%over 5 years

Margins and returns on capital

EXELMRK
Margins and returns on capital
Gross margin96.3%71.8%
Operating margin40.2%–
Net margin35.4%3.6%
ROIC39.9%3.9%
ROE44.5%5.2%

Balance sheet

EXELMRK
Balance sheet
Cash$892M$9.7B
Total debt$162M$53.8B
Net debt / EBITDA-0.95.7
Interest cover–2.4×

Dividends and buybacks

EXELMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield5.7%1.5%
Shareholder yield5.7%4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: EXEL or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Exelixis or Merck & Company?

By market value, Merck & Company ($341B) is about 20.4 times Exelixis ($16.7B), at today's prices.

How did EXEL and MRK stock do over the last 10 years?

Since November 18, 2016, EXEL's price moved +302.7% and MRK's +133.4%. With dividends: EXEL +302.7% (+14.9% a year), MRK +216.6% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, EXEL or MRK?

The dividend yield at today's price is none for Exelixis and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of EXEL and MRK?

At today's price, the P/E is 18.8 for EXEL and 138.9 for MRK. The median of the last five years was 25.4 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Exelixis or Merck & Company?

Over the last twelve months, the net margin was 35.4% for Exelixis and 3.6% for Merck & Company, and the operating margin 40.2% and –. Revenue was $2.5B and $67.4B.

Which is the better investment, Exelixis or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.